Skip to content
Leo Pharma
-
LEO Pharma seeks EU label expansion for Anzupgo in adolescents with chronic hand eczema
The proposed expansion would allow its use in adolescents aged 12 to 17 years with moderate to severe chronic hand eczema (CHE) when topical corticosteroids are inadequate or inappropriate.
-
LEO Pharma to acquire Tanabe’s Dersimelagon for rare photosensitivity disorders
Under the agreement, LEO will pay up to US$435 million in upfront and near-term milestone payments for global rights to dersimelagon.
-
LEO Pharma acquires Replay to advance their gene therapy pipeline for rare genetic skin diseases
LEO Pharma will gain access to Replay’s proprietary high-payload herpes simplex virus (HSV) delivery platform, an innovative technology designed to deliver large therapeutic genes directly into skin cells.